Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

Published:2013-02-06 Issue:2 Volume:8 Page:e56112
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ather Ferdows,Hamidi Habib,Fejzo Marlena S.,Letrent Stephen,Finn Richard S.,Kabbinavar Fairooz,Head Christian,Wong Steven G.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Recent advances in head and neck cancer;RI Haddad;N Engl J Med,2008

2. Profiling early head and neck cancer;KD Hunter;Nat Rev Cancer,2005

3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;DJ Slamon;Science,1987

4. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;RG Amado;J Clin Oncol,2008

5. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines;EB Garon;Mol Cancer Ther,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells;Molecules;2024-01-04

3. Resistance of prostate cancer to kinase inhibitors;Therapy Resistance in Prostate Cancer;2024

4. HPV16 status predicts potential protein biomarkers and therapeutics in head and neck squamous cell carcinoma;Virology;2023-05

5. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors;European Journal of Medicinal Chemistry;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3